| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a3a94888eda15bcc34c9c5c235230463 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4418
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4418
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2018-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2de5a536dabb31b9aebc37f40e895de7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a590232f1751cd09055b6453d54a34e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3382aabbda3f107e58fff650290f72f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c9731343963b104406f0597da9c7fb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17c0463978b91907a45cf98ee79950b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0399391d2af202bbeb12685b641d5ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50f7aa764a49bd685465d0816795c62f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc96753325b7e46491bf63f86df1960c |
| publicationDate |
2022-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11337966-B2 |
| titleOfInvention |
Use of ciclopirox as a modulator of the heme group biosynthesis and in the treatment of porphyrias and other diseases |
| abstract |
The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of a disease caused by dysregulated heme group biosynthesis, with the proviso that said disease is not congenital erythropoietic porphyria. |
| priorityDate |
2017-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |